

First author, year	Population	Rituximab Dose	Number of patients treated with RTX / total patients with post-HSCT AIHA	Response rate Response/total of treated patients
Daikeler, 2013 ²²	Adults and children	Not stated	9/20 as first line, 5/20 as second line	First line: 5/9 CR, 3/9 PR (ORR 88%) Second line: 2/5 CR, 2/5 PR (ORR 80%)
Faraci, 2014 ²⁷	Children	375 mg/m ² /week for 2-5 weeks	1/15 as first line, 7/15 as second line	First line: 100% CR. Second line: 100% CR
Sanz, 2014 ³¹	Adults	375 mg/m ² /week for 4 weeks	4/15 as first line, 4/15 as second line	First line: 2/4 CR, 1/4 PR (ORR 75%) Second line: 4/4 PR (ORR 100%)
Wang, 2015 ⁵	Adults	Not stated	13/19 as second line	38% CR
Ahmed, 2015 ³⁰	Children	Not stated	2/19 as first line, 4/19 as second line	First line: 50% CR. Second line: 25% CR
Bhatt, 2016 ³²	Adults and children	375 mg/m ² /week for 4 weeks	6/8 as first line: 2 RTX alone, 4 with steroids +/- IVIG	CR 50% (but NR with RTX only)
Chang, 2016 ³⁴	Children	375 mg/m ² /week	4/15 as second line	25% CR
Kruizinga, 2018 ²¹	Children	375 mg/m ² /week for 1-3 weeks	1/12 as first line, 6/12 as second line	First line: 100% CR. Second line: 33% CR
Gonzalez-Vicent, 2018 ¹⁶	Adults and children	375 mg/m ² /week for 4 weeks	40/60 (line of treatment not specified)	38% CR
Deambrosis, 2019 ³	Children	Not stated	2/3 as second line	50% CR
Neely, 2019 ¹⁹	Children	Not stated	1/8 RTX only as first line, 5/8 steroid + RTX as first line, 2/8 RTX as second line	First line: CR 16% (steroid + RTX), no other responses
Scordo, 2019 ⁴²	Adults	Not stated	2/10 as first line, 3/10 as second/third line	First line: CR 50%. Second line: 33% CR
Lv, 2019 ²⁵	Adults	Not stated	4/25 as second line	ORR 100%
Miller, 2020 ²⁹	Adults and children	Not stated	5/7 as second line (1 in combination with plasma-apheresis, 1 with CSA)	RTX only: 1/3 CR, 1/3 PR (ORR 66%). Both RTX + CSA or plasmapheresis achieved CR
Lum, 2020 ²⁸	Children	Not stated	11 /19 as second line	CR 54%
Koo, 2020 ¹⁸	Children	375 mg/m ² /week for 4 weeks	First line alone 1/12, with MP 8/12. 4/12 as second line.	First line: 2/9 CR, 7/9 PR (ORR 100%). Second line: 2/4 CR, 1/4 PR (ORR 75%)

Table III: Summary of relevant studies reporting use of Rituximab in post-HSCT AIHA.

Abbreviations: AIHA autoimmune haemolytic anaemia, CR complete remission, CSA cyclosporine, HSCT haematopoietic stem cell transplantation, IVIG Intra-venous Immunoglobulin, MP methylprednisolone, NR no response, ORR overall response rate, PR partial remission, RTX Rituximab.